Information for Lixisenatide
Page information·measured at build time
Technical and provenance information about Lixisenatide. All figures on this page are measured from the emitted page rather than declared.
Basic information
| Display title | Lixisenatide |
|---|---|
| Default sort key | Lixisenatide |
| Namespace | Article (main) |
| Page kind | Compound |
| Page length (source, bytes) | 4,195 |
| Rendered word count | 475 |
| Internal wiki links on the page | 18 |
| Defined citations | 4 |
| Top-level sections | 3 |
| Subsections | 0 |
| Tables | 0 |
| Figures | 0 |
| Infobox | Yes — compound |
| Maintenance banners | None |
| Indexing by robots | Allowed |
Edit history
| Page creator | ColdChainCleo |
|---|---|
| Date of page creation | 4 October 2024 |
| Latest editor | LiraLotte |
| Date of latest edit | 18 July 2026 |
| Total number of edits | 26 |
| Total number of distinct authors | 22 |
| Minor edits | 11 |
| Automated (bot) edits | 1 |
| Recent number of edits (last 90 days) | 3 |
| Talk page posts | 4 |
Principal authors
| Editor | Edits | Share | Declared focus |
|---|---|---|---|
| ComparisonCato | 3 | 11.5% | GLP-1 receptor agonists and related compounds |
| DulaglutideDug | 2 | 7.7% | GLP-1 receptor agonists and related compounds |
| RetatrutideRuben | 2 | 7.7% | GLP-1 receptor agonists and related compounds |
| ColdChainCleo | 1 | 3.8% | peptide synthesis and supply chain |
| HOMA_Hettie | 1 | 3.8% | laboratory medicine and biomarkers |
| AnalyticalAnnie | 1 | 3.8% | analytical chemistry and chromatography |
| LotTraceLuka | 1 | 3.8% | third-party testing and certificates of analysis |
| MolarMassMaeve | 1 | 3.8% | GLP-1 receptor agonists and related compounds |
| StyleSheetSybil | 1 | 3.8% | copy-editing and the manual of style |
| CuriousCallum | 1 | 3.8% | GLP-1 receptor agonists and related compounds |
| SemaglutideSasha | 1 | 3.8% | GLP-1 receptor agonists and related compounds |
| StubSorterBot | 1 | 3.8% | categorisation and navigation |
Category membership
- Category:GLP-1 receptor agonists — 8 member pages
- Category:Peptide drugs — 17 member pages
- Category:Cardiovascular outcome trials — 3 member pages